SCHEMBL80532

SCHEMBL80532

CC(=O)Oc1ccc(CCl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
MAPT P10636 3/20 0.52
POLB P06746 1/20 0.52
PKM P14618 1/20 0.52
ELANE P08246 2/20 0.50
HSD17B10 Q99714 1/20 0.48
ESR1 P03372 1/20 0.47
PGR P06401 1/20 0.47
CHRM2 P08172 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
AR P10275 1/20 0.47
CHRM1 P11229 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
GAA P10253 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HSP90AA1 P07900 1/20 0.47
GSTP1 P09211 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL3154012 0.96 ELANE (0.56) LMNAMAPTPOLBPKMELANE
SCHEMBL28188938 0.87 LMNA (0.47) LMNAMAPTPOLBPKMELANE
SCHEMBL1395475 0.85 CA1 (0.47) LMNAELANEHSD17B10GAACA1
SCHEMBL4113624 0.84 AKT1 (0.55) LMNAMAPTPOLBPKMELANE
SCHEMBL609104 0.83 CA1 (0.48) LMNAMAPTELANEHSD17B10ALDH1A1
SCHEMBL777803 0.83 ELANE (0.62) LMNAMAPTPOLBPKMELANE
SCHEMBL9081470 0.83 LMNA (0.61) LMNAMAPTPOLBPKMELANE
SCHEMBL269329 0.82 LMNA (0.80) LMNAMAPTPOLBPKMELANE
SCHEMBL17343019 0.81 ELANE (0.54) LMNAMAPTPOLBELANEHSD17B10
SCHEMBL68678 0.81 LMNA (0.59) LMNAMAPTPOLBPKMELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374562-A1 METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS EPICENTRX, INC. (US) 2024-11-14 US claimed
US-20140308260-A1 METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS EPICENTRX, INC. 2014-10-16 US claimed
EP-2094292-B1 NITRIC OXIDE-BLOCKED CROSS-LINKED TETRAMERIC HEMOGLOBIN IKOR INC (US) 2014-07-09 EP claimed
WO-2013052803-A2 METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS RADIORX, INC. (US) 2013-04-11 WO claimed
US-20080096805-A1 deoxygenated, endotoxin-free and stroma-free transport proteins, incapable of binding with nitric oxide, useful as substitutes for erythrocytes in mammals and for treating disorders where oxygen delivery agents are of benefit IKOR, INC. 2008-04-24 US claimed
US-20080096803-A1 Carboxymethylated cross-linked tetrameric hemoglobin IKOR, INC. 2008-04-24 US claimed
US-4342877-A Process for the preparation of α-halogenated cresol esters EASTMAN KODAK COMPANY (US) 1982-08-03 US claimed
JP-52156826-A None JP disclosed
US-12617805-B2 Codrug that disintegrates in intestine, preparation therefor, and use thereof ENNOVABIO (ZHEJIANG) PHARMACEUTICALS CO., LTD. (CN) 2026-05-05 US disclosed
US-20260062460-A1 METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS THERIPION, INC. (US) 2026-03-05 US disclosed
US-12509501-B2 Polynucleotides encoding APOA-1 fusion polypeptides THERIPION, INC. (US) 2025-12-30 US disclosed
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-18 US disclosed
US-20250257072-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF SHIONOGI & CO., LTD. (JP) 2025-08-14 US disclosed
JP-S52156826-A PREPARATION OF P-HYDROXYBENZALDEHYDE KUREHA CHEM IND CO LTD 1977-12-27 JP disclosed
US-4045438-A Cephalosporin antibiotics YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 1977-08-30 US disclosed
US-4031083-A Cephalosporin antibiotics YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) 1977-06-21 US disclosed
US-4026887-A Cephalosporin antibiotics YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) 1977-05-31 US disclosed
US-3994875-A CEPHALOSPORINS, PENICILLINS YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) 1976-11-30 US disclosed
US-3993661-A Quinone methide photograhpic reagent precursors POLAROID CORPORATION (US) 1976-11-23 US disclosed
US-3948904-A ANTIBIOTICS YEDA RESEARCH & DEVELOPMENT CO. LTD. (IL) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062460-A1 METHODS FOR TREATING ACUTE CORONARY SYNDROME USING APOA-1 FUSION PROTEINS PON1, APOB, APOL1 LMNA 600/4885MAPT 3644/4885POLB 2437/4885
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS ACHE, BCHE, DDT LMNA 3388/4885MAPT 1033/4885POLB 4588/4885
US-12509501-B2 Polynucleotides encoding APOA-1 fusion polypeptides APOB, PON1, APOL1 LMNA 419/4885MAPT 2602/4885POLB 555/4885
US-20250257072-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUG THEREOF C3AR1, CYP4B1, ADORA2B LMNA 2305/4885MAPT 4806/4885POLB 459/4885
US-20240374562-A1 METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS HBB, HBG2, HBZ LMNA 2548/4885MAPT 4665/4885POLB 2076/4885
US-20140308260-A1 METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS HBB, HBG2, HBZ LMNA 2548/4885MAPT 4665/4885POLB 2076/4885
US-12617805-B2 Codrug that disintegrates in intestine, preparation therefor, and use thereof IRAK4, JAK1, VIP LMNA 3587/4885MAPT 4003/4885POLB 1110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.